Markopoulos C, Polychronis A, Dafni U, Koukouras D, Zobolas V, Tzorakoleftherakis E, Xepapadakis G, Gogas H
Department of Breast Surgery, Medical School, University of Athens, Athens, Greece.
Ann Oncol. 2009 Jan;20(1):49-55. doi: 10.1093/annonc/mdn545. Epub 2008 Aug 4.
The Greek substudy of the Tamoxifen and Exemestane Adjuvant Multicenter International trial compared the effect of exemestane on the lipid profile of postmenopausal, breast cancer patients to that of tamoxifen in the adjuvant setting.
Lipidemic profile changes were studied in 142 postmenopausal patients randomized to receive either adjuvant exemestane (n=77) or tamoxifen (n=65). Total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL) and serum triglyceride (TRG) levels were measured at baseline and then every 3 months for the first 12 months of treatment and at 18 and 24 months.
A trend for a reduction in TC was found in both treatment arms; however, TC and LDL levels were consistently and significantly decreased in tamoxifen arm only. The mean HDL level was higher for the tamoxifen arm compared with the exemestane arm across time. No significant trend was detected throughout the study period on TRG levels on either arm.
Unlike tamoxifen's beneficial effect on TC and LDL levels, exemestane appears to have a neutral effect on lipidemic profile of postmenopausal, breast cancer patients. These data offer additional information with regard to the safety and tolerability of exemestane treatment in the adjuvant setting.
他莫昔芬与依西美坦辅助治疗多中心国际试验的希腊子研究，在辅助治疗环境中比较了依西美坦与他莫昔芬对绝经后乳腺癌患者血脂谱的影响。
对142例随机接受辅助依西美坦（n = 77）或他莫昔芬（n = 65）治疗的绝经后患者的血脂变化进行了研究。在基线时测量总胆固醇（TC）、高密度脂蛋白（HDL）、低密度脂蛋白（LDL）和血清甘油三酯（TRG）水平，然后在治疗的前12个月每3个月测量一次，以及在18个月和24个月时测量。
两个治疗组均发现TC有降低趋势；然而，仅他莫昔芬组的TC和LDL水平持续且显著降低。在整个时间段内，他莫昔芬组的平均HDL水平高于依西美坦组。在整个研究期间，两组的TRG水平均未检测到显著趋势。
与他莫昔芬对TC和LDL水平的有益作用不同，依西美坦似乎对绝经后乳腺癌患者的血脂谱有中性影响。这些数据为依西美坦辅助治疗的安全性和耐受性提供了更多信息。
Zotero 插件